Best peptides for longevity
Peptides researched for lifespan extension, cellular rejuvenation, and healthy aging at the biological level.
Longevity peptides target the biology of aging itself — from telomere maintenance and senescent cell clearance to mitochondria-derived cytoprotective signals. The field ranges from well-studied compounds like Epithalon (40+ years of research) to cutting-edge senolytics like FOXO4-DRI that have only one landmark mouse study behind them. Here is where the evidence stands for each.
Anti-aging collagen stimulator widely used in anti-aging serums. One of the most well-studied cosmetic peptides with a strong track record for reducing fine lines.
What evidence supports
- ✓stimulates collagen I and fibronectin production in fibroblasts
- ✓may reduce wrinkle depth with consistent use over 8–12 weeks
- ✓well-tolerated in clinical studies
Key concern: rarely irritating but possible with very sensitive skin
Available in
A collagen-boosting signal peptide most often paired with Palmitoyl Tetrapeptide-7 to form the Matrixyl 3000 complex. Popular in anti-aging formulations aimed at mature or sensitive skin.
What evidence supports
- ✓in vitro studies show stimulation of collagen I and III production in fibroblasts
- ✓modest wrinkle reduction observed in in vivo studies over several weeks
- ✓generally well-tolerated including in sensitive skin
Key concern: typically well-tolerated with minimal irritation risk
Available in
A 21-amino acid peptide encoded in the mitochondrial genome, discovered in 2001 as a neuroprotective factor. Humanin levels decline sharply with age and in Alzheimer's disease. Emerging research links it to longevity, insulin sensitivity, and cytoprotection — though human data remains preliminary.
What evidence supports
- ✓plasma Humanin significantly lower in Alzheimer's patients vs healthy age-matched controls
- ✓neuroprotection against Aβ toxicity in cell culture and mouse models
- ✓extends lifespan in C. elegans; improves healthspan markers in mice
Key concern: no completed human clinical trials for longevity or cognitive indications
A palmitoylated tripeptide developed by DSM (now dsm-firmenich) under the trademark Syn-Coll. Designed to stimulate collagen synthesis via the TGF-β signaling pathway, offering a mechanistic complement to Matrixyl-type peptides that work through extracellular matrix fragment mimicry.
What evidence supports
- ✓in vitro: Pal-Lys-Val-Lys significantly increases Type I collagen expression in human fibroblast cultures
- ✓manufacturer-sponsored in vivo study: improved skin firmness and wrinkle depth reduction after 84 days at 3% concentration
- ✓mechanism via TGF-β1 pathway is pharmacologically plausible and supported by cell culture data
Key concern: clinical evidence primarily manufacturer-sponsored (DSM) with limited independent trials
A mitochondrial-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. MOTS-c has gained significant attention in longevity and metabolic health communities for its exercise-mimicking effects and role in cellular energy regulation. Research is promising but still early-stage.
What evidence supports
- ✓activates AMPK signaling pathway in cell and animal studies
- ✓improved glucose metabolism and insulin sensitivity in mouse models
- ✓exercise-induced increase in circulating MOTS-c levels documented in humans
Key concern: no completed human clinical trials for therapeutic use
A synthetic mitochondrial-targeted peptide that concentrates in the inner mitochondrial membrane. Developed for mitochondrial diseases and heart failure, SS-31 has gained significant attention in the longevity community for its potential to restore age-related mitochondrial dysfunction.
What evidence supports
- ✓improved mitochondrial function and reduced ROS in multiple animal models of aging
- ✓restored cardiac function in animal models of heart failure
- ✓human clinical trials completed for Barth syndrome (rare mitochondrial disease) with measurable improvements
Key concern: not FDA-approved — failed to meet primary endpoint in pivotal Barth syndrome trial despite showing biological activity
A grouping of longevity-focused experimental peptides aimed at boosting cellular NAD+ levels, clearing senescent cells, or stimulating telomerase. Largely experimental with very preliminary human data.
What evidence supports
- ✓promising cell and animal studies on senolytic mechanisms (FOXO4-DRI)
- ✓some animal data on telomere-related effects (Epitalon)
- ✓NAD+ pathway research is active and growing, though largely preclinical
Key concern: mostly experimental — not FDA approved for any indication
Available in
A synthetic tripeptide (Glu-Asp-Arg) developed by the Khavinson group at the St. Petersburg Institute of Bioregulation. Designed as a bioregulator for the pineal gland, claimed to support circadian rhythm, cognitive function, and antioxidant defense. Evidence comes primarily from Russian laboratory research with limited independent replication.
What evidence supports
- ✓in vitro: EDR peptide reduces oxidative stress markers in neural cell cultures
- ✓Russian clinical reports: improvements in sleep and cognitive metrics in elderly patients
- ✓animal studies: neuroprotective effects in ischemia models
Key concern: almost all evidence originates from the same Russian research group (Khavinson et al.) with limited independent verification
A polypeptide complex isolated from bovine thymus gland, developed by the Khavinson group as a bioregulator for immune function. One of the most clinically-studied Khavinson bioregulators, used in Russia for immune support in elderly and cancer patients. Often paired with Epithalon in longevity protocols.
What evidence supports
- ✓longitudinal study (Khavinson, 2003): elderly patients treated with Thymalin + Epithalon over 6–8 years showed reduced all-cause mortality vs untreated age-matched controls
- ✓clinical reports of improved T-cell counts in elderly patients with repeat dosing
- ✓reduces incidence of respiratory infections in elderly institutional patients per Russian clinical data
Key concern: longevity study lacked rigorous placebo controls and randomization by modern RCT standards
A synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed by the Khavinson group as a bioregulator for cardiovascular tissue. Designed to support cardiac function, coronary vessel health, and cardiomyocyte survival under stress. Evidence is limited to the originating Russian research group with no independent clinical replication.
What evidence supports
- ✓in vitro (Khavinson group): AEDP peptide reduces cardiomyocyte apoptosis under oxidative stress
- ✓small clinical reports of improved cardiac function markers in elderly patients
- ✓animal ischemia models show cardioprotective signal
Key concern: all evidence from a single Russian research group with no independent replication
The simplest of the Khavinson bioregulators: a synthetic dipeptide of lysine and glutamic acid (Lys-Glu). Originally derived from the thymus, Vilon is proposed to modulate immune function, reduce inflammation, and slow biological aging. Its small size gives it potentially higher oral bioavailability than larger bioregulator peptides — though this is theoretical.
What evidence supports
- ✓extends lifespan in Drosophila and mice in Russian animal studies
- ✓Russian clinical data: reduced all-cause mortality in elderly populations with combined Vilon + Epithalon regimens
- ✓cell culture studies: KE peptide can modulate gene expression in immune and epithelial cell lines
Key concern: evidence exclusively from Khavinson research group — no independent replication
A D-retro-inverso (DRI) modified peptide that disrupts the FOXO4-p53 protein interaction that keeps senescent cells ("zombie cells") alive. By restoring apoptosis in senescent cells, FOXO4-DRI acts as a targeted senolytic — eliminating senescent cells while sparing healthy tissue. Demonstrated dramatic rejuvenating effects in aged mice in a landmark 2017 Cell paper. No human trials have been completed.
What evidence supports
- ✓mouse study (Baar et al., Cell, 2017): weekly IP injection restored fur density, exercise capacity, and physical appearance in fast-aged XPD mice; also reversed chemotherapy-induced physical decline
- ✓selectively induced apoptosis in senescent but not normal human fibroblasts in culture
- ✓the FOXO4-p53 survival mechanism in senescent cells confirmed in human cell data
Key concern: no human clinical trials have been completed — only one mouse study published
A synthetic tetrapeptide studied for its potential to activate telomerase, the enzyme that maintains telomere length. Developed by Russian scientist Vladimir Khavinson and central to his theory of peptide bioregulation. Human evidence is very preliminary.
What evidence supports
- ✓in vitro studies show telomerase activation in human somatic cells
- ✓rodent studies by Khavinson group reported increased lifespan in some models
- ✓some evidence of melatonin normalization in elderly subjects in small studies
Key concern: the vast majority of research comes from a single lab group, raising replication concerns
A small molecule NNMT inhibitor that has gained popularity in biohacking and weight-loss communities for its potential to boost cellular energy expenditure and reduce fat accumulation. Technically not a peptide, but widely discussed and sold alongside peptides in the metabolic health space.
What evidence supports
- ✓NNMT inhibition reduced body weight and fat mass in diet-induced obese mice
- ✓cell studies show NNMT inhibition increases NAD+ levels and energy expenditure in adipocytes
- ✓NNMT is overexpressed in adipose tissue of obese individuals (validated target)
Key concern: no published human clinical trials — all evidence is preclinical
Available in
Not sure which is right for you?
Take our quiz for a personalized recommendation based on your goals and preferences.
Take the Peptide QuizMedical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.